Neuland Laboratories Ltd

Neuland Laboratories Limited — Closure of Trading Window from October 1, 2026 till 48 hours after the declaration of financial results for the quarter and half year ended September 30, 2026

Meeting Details

• Dates: September 23–25, 2026; times not disclosed.
• Type: group and one-on-one meetings; mode: physical in Singapore.
• Event: Goldman Sachs Global Healthcare CDMO Day.
• Participants: company management; company secretary (signatory).
• Purpose: investor interaction during group/one-on-one meetings.

Module 1 operational

• First commercial peptide manufacturing module is now operational, enabling 7000 L reactor capacity.

Module 2 expansion plan

• Module 2 capacity slated up to 18,000 L with three LPPS reactors.

Capex and future investments

• USD 30 million invested in Module 1; additional investments planned for later modules.

Revenue context

• Revenues rose 116% in the most recent quarterly results.

Capacity context

• Total reactor capacity across Neuland facilities about 1,218 kL.

Market trajectory

• Oncology programs emerging as a key growth area; outsourcing demand expanding.

Strategic outlook

• Management intends to align capacity with demand over the next decade.

Meeting Details

• Sept 15, 2026: Group meeting with Emkay Global Investors, Hyderabad.
• Sept 17, 2026: Group meeting for ICICI Securities, Hyderabad Healthcare Day.

Participants

• Neuland Laboratories management to participate.

Purpose

• Group analyst/institutional investor meetings for investor interaction.

Capex for land purchase

• Board approved ₹126 crore capex to acquire ~134 acres at Auro Industrial City, Kakinada; internal accruals.
• Right of first refusal to buy an additional ~66 acres, potentially expanding land to ~200 acres.

Rating Action

• Long-Term rating reaffirmed at CRISIL A+ with Positive outlook.
• Short-Term rating reaffirmed at CRISIL A1.

Sale under Reg 29(2)

• Target Company: Neuland Laboratories Limited.
• Disclosing Party: Malabar India Fund Limited (non-promoter).
• Transaction Type: Sale of equity shares in open market.
• Pre-Transaction Holding: 9,21,371 shares, 7.18%.
• Encumbrances pre-sale: Nil.
• Details of sale: 2,72,634 shares sold (2.12%).
• Mode of sale: Open market.
• Post-Transaction Holding: 6,48,737 shares, 5.06%.
• Date(s) of Transaction: Between 10 August 2024 and 14 August 2026.
• Equity capital before sale: Rs 12,82,98,890; 1,28,29,889 shares.
• Equity capital after sale: Rs 12,82,98,890; 1,28,29,889 shares.
• Total diluted capital after sale: Rs 12,82,98,890; 1,28,29,889 shares.

FDA Form 483 observation

• US FDA Form 483 issued with one observation on water and environmental monitoring procedures beyond USP.
• Facility: Unit 3, Gaddapotharam village, Jinnaram, Sangareddy District.
• Inspection conducted 10–14 August 2026; response due within timelines.

Financial Performance

• Q1FY27 total income INR 650.1 crores, up 16.3% YoY from INR 300.6 crores.
• EBITDA INR 231.1 crores, margin 35.5%.
• Gross margin 61.2% vs 55.3% in Q1FY26.
• PAT INR 147.4 crores; EPS INR 114.9.
• Working capital days improved to 84 in FY27 from 137.
• Capex outflow INR 121.6 crores in Q1FY27 for R&D and peptide facilities.
• Approved capex during quarter ~ INR 203 crores; 196 crores for Unit 1 capacity expansion.
• Total approved capex INR 1,460 crores over 13 quarters; INR 870 crores spent to date.
• Peptide plant commissioned next month; manufacturing qualification underway.
• Gland Pharma collaboration for sterile API manufacturing.
• Future expansion may require additional manufacturing sites beyond three current sites.

GDS & CMS Update

• GDS growth driven by Ezetimibe, Mirtazapine, Escitalopram, Aripiprazole.
• Expanding presence in Brazil, Japan, South Korea and Turkey.
• CMS pipeline: two new development projects; growth from development to commercial.
• Peptide capabilities: plant commissioning next month; module 1 utilization improving.
• Gland Pharma collaboration shows synergy; niche sterile API focus.
• Outlook remains in line with long-term ambitions for FY27/FY28.
• Quarterly results can be uneven; lumpiness expected.

Balance Sheet and Cash Flow

• Working capital optimization; 84 days cash conversion improved.
• Capex outflow INR 121.6 crores in Q1FY27.
• Capex approvals during quarter INR 203 crores; 196 crores Unit 1.
• Total approved capex INR 1,460 crores; 870 crores spent to date.
• Currently three manufacturing sites; future land expansion planned.
• Future capex higher; possible overseas investments or acquisitions.

Projects and Capex

• Peptide plant commissioning next month; manufacturing qualification following.
• Gland Pharma collaboration for sterile APIs; niche product focus.
• Capex for capacity expansion at Unit 1; part of growth.
• Investments in R&D, peptides, sterile APIs; higher quantum and complexity.
• Future capex higher; overseas investments or M&A possible.

Outlook and Guidance

• FY27 expected to be a year of growth; long-term ambitions intact.
• Long-term growth target around 20% annually.
• FY28 growth likely; lumpiness possible; not a fixed FY27 number.
• Destocking not expected to hit abruptly; order visibility consistent.

Q&A Highlights

• Development revenues expected to rise; two new projects in FY27.
• CMS growth driven by handful of molecules; diversification over time.
• One more commercialization this year; more next year.
• Peptide plant will enable future opportunities beyond Module 1 capacity.
• Development revenue vs commercial base not quantified now; may rise.